T Sonia Boender1, Raph L Hamers2, Pascale Ondoa1, Maureen Wellington3, Cleophas Chimbetete3, Margaret Siwale4, Eman E F Labib Maksimos5, Sheila N Balinda6, Cissy M Kityo6, Titilope A Adeyemo7, Alani Sulaimon Akanmu7, Kishor Mandaliya8, Mariette E Botes9, Wendy Stevens10, Tobias F Rinke de Wit1, Kim C E Sigaloff2. 1. Amsterdam Institute for Global Health and Development, Department of Global Health. 2. Amsterdam Institute for Global Health and Development, Department of Global Health Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, The Netherlands. 3. Newlands Clinic, Harare, Zimbabwe. 4. Lusaka Trust Hospital. 5. Coptic Hospital, Lusaka, Zambia. 6. Joint Clinical Research Centre, Kampala, Uganda. 7. Department of Haematology & Blood transfusion, College of Medicine of the University of Lagos, Nigeria. 8. Coast Province General Hospital, Mombasa, Kenya. 9. Muelmed Hospital, Pretoria. 10. Department of Molecular Medicine and Haematology, University of the Witwatersrand, and the National Health Laboratory Service, Johannesburg, South Africa.
Abstract
BACKGROUND: As antiretroviral therapy (ART) programs in sub-Saharan Africa mature, increasing numbers of persons with human immunodeficiency virus (HIV) infection will experience treatment failure, and require second- or third-line ART. Data on second-line failure and development of protease inhibitor (PI) resistance in sub-Saharan Africa are scarce. METHODS: HIV-1-infected adults were included if they received >180 days of PI-based second-line ART. We assessed risk factors for having a detectable viral load (VL, ≥400 cps/mL) using Cox models. If VL was ≥1000 cps/mL, genotyping was performed. RESULTS: Of 227 included participants, 14.6%, 15.2% and 11.1% had VLs ≥400 cps/mL at 12, 24, and 36 months, respectively. Risk factors for a detectable VL were as follows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ratio, 7.10; 95% confidence interval, 3.40-14.83; P < .001) or PI-based (7.59; 3.02-19.07; P = .001) first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.69; 2.49-17.98; P < .001), and suboptimal adherence (3.05; 1.71-5.42; P = .025). Among participants with VLs ≥1000 cps/mL, 22 of 32 (69%) harbored drug resistance mutation(s), and 7 of 32 (22%) harbored PI resistance. CONCLUSIONS: Although VL suppression rates were high, PI resistance was detected in 22% of participants with VLs ≥1000 cps/mL. To ensure long-term ART success, intensified support for adherence, VL and drug resistance testing, and third-line drugs will be necessary.
BACKGROUND: As antiretroviral therapy (ART) programs in sub-Saharan Africa mature, increasing numbers of persons with human immunodeficiency virus (HIV) infection will experience treatment failure, and require second- or third-line ART. Data on second-line failure and development of protease inhibitor (PI) resistance in sub-Saharan Africa are scarce. METHODS:HIV-1-infected adults were included if they received >180 days of PI-based second-line ART. We assessed risk factors for having a detectable viral load (VL, ≥400 cps/mL) using Cox models. If VL was ≥1000 cps/mL, genotyping was performed. RESULTS: Of 227 included participants, 14.6%, 15.2% and 11.1% had VLs ≥400 cps/mL at 12, 24, and 36 months, respectively. Risk factors for a detectable VL were as follows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ratio, 7.10; 95% confidence interval, 3.40-14.83; P < .001) or PI-based (7.59; 3.02-19.07; P = .001) first-line regimen compared with zidovudine/lamivudine/NNRTI, PI resistance at switch (6.69; 2.49-17.98; P < .001), and suboptimal adherence (3.05; 1.71-5.42; P = .025). Among participants with VLs ≥1000 cps/mL, 22 of 32 (69%) harbored drug resistance mutation(s), and 7 of 32 (22%) harbored PI resistance. CONCLUSIONS: Although VL suppression rates were high, PI resistance was detected in 22% of participants with VLs ≥1000 cps/mL. To ensure long-term ART success, intensified support for adherence, VL and drug resistance testing, and third-line drugs will be necessary.
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: Pascale Ondoa; Andrea A Kim; T Sonia Boender; Guoqing Zhang; Stefanie Kroeze; Jeffrey Wiener; Tobias Rinke de Wit; John Nkengasong Journal: AIDS Res Hum Retroviruses Date: 2020-08-27 Impact factor: 2.205
Authors: J Ross; A Jiamsakul; N Kumarasamy; I Azwa; T P Merati; C D Do; M P Lee; P S Ly; E Yunihastuti; K V Nguyen; R Ditangco; O T Ng; J Y Choi; S Oka; A H Sohn; M Law Journal: HIV Med Date: 2020-11-05 Impact factor: 3.180
Authors: Carole L Wallis; Michael D Hughes; Justin Ritz; Raquel Viana; Carlos Silva de Jesus; Shanmugam Saravanan; Marije van Schalkwyk; Rosie Mngqibisa; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Laura Hovind; Linda Wieclaw; Robert Gross; Catherine Godfrey; Ann C Collier; Beatriz Grinsztejn; John W Mellors Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 20.999
Authors: Aastha Gupta; Sandeep Juneja; Marco Vitoria; Vincent Habiyambere; Boniface Dongmo Nguimfack; Meg Doherty; Daniel Low-Beer Journal: PLoS One Date: 2016-10-13 Impact factor: 3.240